Boundless Bio Announces Presentations at Two January Conferences
SAN DIEGO--(BUSINESS WIRE)--Jan 7, 2020--
Boundless Bio, a company interrogating and targeting extrachromosomal DNA (ecDNA) in aggressive cancers, today announced presentations at the following upcoming conferences:
Extrachromosomal DNA, or ecDNA, are large circles of DNA containing genes that are outside the cells’ chromosomes and can make many copies of themselves. ecDNA can be rapidly replicated within the cell, causing high numbers of oncogene copies, a trait that can be passed to daughter cells in asymmetric ways during cell division. Cells have the ability to upregulate or downregulate ecDNA and resulting oncogenes to ensure survival under selective pressures, including chemotherapy or radiation, making ecDNA one of cancer cells’ primary mechanisms of recurrence and treatment evasion. ecDNA are rarely seen in healthy cells but are found in many solid tumor cancers. They are a key driver of the most aggressive and difficult-to-treat cancers, specifically those characterized by high copy number amplification of oncogenes.
About Boundless Bio
Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers. For more information, visit www.boundlessbio.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20200107005220/en/
CONTACT: Sarah Sutton
Glover Park Group
Glover Park Group
KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY GENETICS ONCOLOGY RESEARCH SCIENCE GENERAL HEALTH
SOURCE: Boundless Bio
Copyright Business Wire 2020.
PUB: 01/07/2020 08:30 AM/DISC: 01/07/2020 08:30 AM